Evaluation of KCTD12 and Cripto-1 as novel upregulated proteins participating in breast cancer development and drug resistance
Ragab, M., Sallam, A., Amer, E., El Mesallamy, H. (2022). Evaluation of KCTD12 and Cripto-1 as novel upregulated proteins participating in breast cancer development and drug resistance. EKB Journal Management System, 65(1), 665-672. doi: 10.21608/ejchem.2021.84960.4141
Mamdouh Aboelfath Ragab; Al-Aliaa Mohamed Sallam; Eman Abdelaleem Amer; Hala Osman El Mesallamy. "Evaluation of KCTD12 and Cripto-1 as novel upregulated proteins participating in breast cancer development and drug resistance". EKB Journal Management System, 65, 1, 2022, 665-672. doi: 10.21608/ejchem.2021.84960.4141
Ragab, M., Sallam, A., Amer, E., El Mesallamy, H. (2022). 'Evaluation of KCTD12 and Cripto-1 as novel upregulated proteins participating in breast cancer development and drug resistance', EKB Journal Management System, 65(1), pp. 665-672. doi: 10.21608/ejchem.2021.84960.4141
Ragab, M., Sallam, A., Amer, E., El Mesallamy, H. Evaluation of KCTD12 and Cripto-1 as novel upregulated proteins participating in breast cancer development and drug resistance. EKB Journal Management System, 2022; 65(1): 665-672. doi: 10.21608/ejchem.2021.84960.4141

Evaluation of KCTD12 and Cripto-1 as novel upregulated proteins participating in breast cancer development and drug resistance

Egyptian Journal of Chemistry
Article 64, Volume 65, Issue 1, January 2022, Page 665-672  XML PDF (866.69 K)
Document Type: Original Article
DOI: 10.21608/ejchem.2021.84960.4141
View on SCiNiTO View on SCiNiTO
Authors
Mamdouh Aboelfath Ragaborcid 1; Al-Aliaa Mohamed Sallam2; Eman Abdelaleem Amer1; Hala Osman El Mesallamy email orcid 3
1Biochemistry, Pharmacy, Ahram Canadian University, Giza, Egypt
2Biochemisty, Pharmacy, Ain Shams, Cairo, Egypt
3Biochemistry, Faculty of Pharmacy, Sinai University, Sinai, Egypt
Abstract
Background: Potassium channel tetramerization domain containing 12 (KCTD12) showed contradictory roles in many cancers, however, its role in breast cancer is unknown. Cripto-1 participates activates the Notch signaling pathway which was inhibited by KCTD12 in esophageal squamous cell carcinoma (ESCC). Uncoordinated 51-like kinase 2 (ULK2) with established roles in cancer was negatively regulated by KCTD12. Multidrug resistance protein 1 (MDR1) promotes resistance by an active transport efflux pump. KCTD12 downregulates the expression of drug-resistant proteins as ABCC4 and ABCG2 in ESCC patients.
Purpose: We investigated the markers role in the early breast cancer.
Methods: Sixty-five patient’s serum samples were compared with 10 controls and 15 benign ones.
Results: Higher serum levels of KCTD12, Cripto-1, MDR1, and ULK2 in all malignant cases suggesting novel roles with better sensitivity and specificity along with CA15.3, where the resistant group was the highest suggesting value for de-novo breast cancer diagnosis.
Conclusion: Positive correlations for KCTD12 with Cripto-1, MDR1, and ULK2 suggesting a new role of KCTD12. The cumulated ROC curves with CA15.3 revealed better sensitivity and specificity highlighting the add on of using more than one marker.
Keywords
Breast Cancer; Cripto-1; MDR1; Notch signaling; Potassium channel tetramerization domain containing 12; Uncoordinated 51-like kinase 2
Statistics
Article View: 457
PDF Download: 162